{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:55:46Z","timestamp":1790837746810,"version":"4.1.0"},"reference-count":92,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Systemic sclerosis-associated pulmonary hypertension (SSc-PH) is a heterogeneous, difficult-to-treat condition in which multiple pulmonary hypertension groups frequently overlap. Recent evidence suggests that vascular involvement may contribute to multiple SSc-PH phenotypes. This review highlights recent advances in understanding vascular features and emerging therapeutic strategies beyond vasodilation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Pathological and imaging studies demonstrate that vascular remodeling in SSc-PH extends beyond pulmonary arteries to pulmonary veins, capillaries, and coronary microcirculation, consistent with widespread immune-mediated vascular dysfunction. These features are increasingly recognized across various SSc-PH phenotypes: pulmonary arterial hypertension and pulmonary veno-occlusive disease; pulmonary hypertension associated with left heart disease, most commonly heart failure with preserved ejection fraction (PH-HFpEF); and pulmonary hypertension-associated with interstitial lung disease (PH-ILD); each of which is often accompanied by intrinsic right ventricular (RV) dysfunction. Emerging therapies targeting activin signaling, macrophage\u2013vascular crosstalk, B-cell immunity, and endothelial-to-mesenchymal transition require further study but may be essential to identifying disease-modifying approaches across SSc-PH phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>There is increasing recognition that vascular remodeling across the cardiopulmonary circulation may underlie multiple SSc-PH phenotypes, providing novel insight into SSc-PH disease mechanisms and rationale for the development of therapies targeting vascular remodeling, fibrosis, inflammation, and intrinsic RV dysfunction beyond conventional vasodilator treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001202","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:00:17Z","timestamp":1788415217000},"page":"369-377","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Redefining systemic sclerosis-associated pulmonary hypertension as an immune-mediated vasculopathy across the cardiopulmonary circulation"],"prefix":"10.1097","volume":"38","author":[{"given":"Ai","family":"Yaku","sequence":"first","affiliation":[{"name":"Division of Cardiology"},{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben J.","family":"Mylvaganam","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"2401324","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J Rheumatol"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/rccm.202204-0731OC","article-title":"Improved survival for patients with systemic sclerosis-associated pulmonary arterial hypertension: the Johns Hopkins Registry","volume":"207","author":"Hassan","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1378\/chest.12-0653","article-title":"Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era","volume":"144","author":"Rubenfire","year":"2013","journal-title":"Chest"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2332\/allergolint.11-RAI-0337","article-title":"A histopathological study of pulmonary hypertension in connective tissue disease","volume":"60","author":"Sasaki","year":"2011","journal-title":"Allergol Int"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","article-title":"Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases","volume":"38","author":"Dorfmuller","year":"2007","journal-title":"Hum Pathol"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/art.34501","article-title":"Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension","volume":"64","author":"Gunther","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1183\/09031936.00106008","article-title":"Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy","volume":"34","author":"Overbeek","year":"2009","journal-title":"Eur Respir J"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/ard.2006.057760","article-title":"Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis","volume":"67","author":"de Groote","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/2045893217700438","article-title":"Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction","volume":"7","author":"Bourji","year":"2017","journal-title":"Pulm Circ"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction","volume":"137","author":"Fayyaz","year":"2018","journal-title":"Circulation"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.120.045810","article-title":"Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF Study","volume":"142","author":"Sanders-van Wijk","year":"2020","journal-title":"Circulation"},{"key":"R14-20261001","first-page":"1005","article-title":"Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease","volume":"34","author":"Launay","year":"2007","journal-title":"J Rheumatol"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1378\/chest.07-0116","article-title":"High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis","volume":"132","author":"Zisman","year":"2007","journal-title":"Chest"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12931-020-01570-2","article-title":"Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights","volume":"21","author":"Ruffenach","year":"2020","journal-title":"Respir Res"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/acr2.1003","article-title":"Capillary proliferation in systemic-sclerosis-related pulmonary fibrosis: association with pulmonary hypertension","volume":"1","author":"Seki","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1183\/23120541.00168-2018","article-title":"Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation","volume":"5","author":"Gupta","year":"2019","journal-title":"ERJ Open Res"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1378\/chest.11-0449","article-title":"Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis","volume":"141","author":"Mura","year":"2012","journal-title":"Chest"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1465-9921-11-37","article-title":"Iron deposition and increased alveolar septal capillary density in nonfibrotic lung tissue are associated with pulmonary hypertension in idiopathic pulmonary fibrosis","volume":"11","author":"Kim","year":"2010","journal-title":"Respiratory Research"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.200912-1820OC","article-title":"Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension","volume":"182","author":"Campo","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1161\/CIRCULATIONAHA.117.033147","article-title":"Right ventricular myofilament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension","volume":"137","author":"Hsu","year":"2018","journal-title":"Circulation"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"1701436","DOI":"10.1183\/13993003.01436-2017","article-title":"Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension","volume":"50","author":"Mukherjee","year":"2017","journal-title":"Eur Respir J"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.112.000008","article-title":"Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension","volume":"6","author":"Tedford","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R25-20261001","first-page":"1941","article-title":"High prevalence of right ventricular systolic dysfunction in early systemic sclerosis","volume":"31","author":"Meune","year":"2004","journal-title":"J Rheumatol"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"e003792","DOI":"10.1161\/CIRCIMAGING.115.003792","article-title":"Unique abnormalities in right ventricular longitudinal strain in systemic sclerosis patients","volume":"9","author":"Mukherjee","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"(5 Suppl 62)","key":"R27-20261001","first-page":"S48","article-title":"Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin","volume":"28","author":"Allanore","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/eurjhf\/hfp198","article-title":"Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of long-term left ventricular dysfunction and remodeling in systemic sclerosis: 7-year follow-up study","volume":"12","author":"Mizuno","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/rheumatology\/keq402","article-title":"Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies","volume":"50","author":"Pinter","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1253\/circj.CJ-14-1114","article-title":"Coronary microvascular dysfunction in asymptomatic patients affected by systemic sclerosis - limited vs. diffuse form","volume":"79","author":"Faccini","year":"2015","journal-title":"Circ J"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.CIR.53.3.483","article-title":"Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction","volume":"53","author":"Bulkley","year":"1976","journal-title":"Circulation"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"e0126707","DOI":"10.1371\/journal.pone.0126707","article-title":"Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy","volume":"10","author":"Mueller","year":"2015","journal-title":"PLoS One"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.50.4.844","article-title":"De subitaneis mortibus. VIII. Coronary arteries and conduction system in scleroderma heart disease","volume":"50","author":"James","year":"1974","journal-title":"Circulation"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3899\/jrheum.090661","article-title":"Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group","volume":"37","author":"Kowal-Bielecka","year":"2010","journal-title":"J Rheumatol"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"e009362","DOI":"10.1161\/JAHA.118.009362","article-title":"Lack of a tricuspid regurgitation Doppler signal and pulmonary hypertension by invasive measurement","volume":"7","author":"O\u2019Leary","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar3876","article-title":"N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study","volume":"14","author":"Thakkar","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-015-0517-5","article-title":"A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis","volume":"17","author":"Hao","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/art.41732","article-title":"Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort","volume":"73","author":"Young","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/art.42791","article-title":"Performance of DETECT Pulmonary Arterial Hypertension Algorithm according to the hemodynamic definition of pulmonary arterial hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines","volume":"76","author":"Distler","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/art.38029","article-title":"Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis","volume":"65","author":"Lefevre","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R42-20261001","first-page":"1590","article-title":"Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions","volume":"42","author":"Erdogan","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/eurheartj\/ehr160","article-title":"Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward","volume":"32","author":"Lau","year":"2011","journal-title":"Eur Heart J"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jacc.2015.05.032","article-title":"Prediction of future overt pulmonary hypertension by 6-min walk stress echocardiography in patients with connective tissue disease","volume":"66","author":"Kusunose","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13075-015-0673-7","article-title":"Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension","volume":"17","author":"Nagel","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R46-20261001","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.jacc.2023.09.807","article-title":"Exercise stress echocardiography of the right ventricle and pulmonary circulation","volume":"82","author":"Gargani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R47-20261001","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s10554-021-02237-9","article-title":"Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis","volume":"37","author":"Mukherjee","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"R48-20261001","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.07-2324","article-title":"Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis","volume":"134","author":"Steen","year":"2008","journal-title":"Chest"},{"key":"R49-20261001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/23971983231199148","article-title":"Use of exercise tests in screening for pulmonary arterial hypertension in systemic sclerosis: a systematic literature review","volume":"9","author":"Madigan","year":"2024","journal-title":"J Scleroderma Relat Disord"},{"key":"R50-20261001","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/ehjci\/jeaf025","article-title":"Role of Exercise Stress Echocardiography in Systemic Sclerosis: Pathophysiological and Prognostic Significance of the Systemic Sclerosis with a Heart Failure and Preserved Ejection Fraction Phenotype","volume":"26","author":"Yuasa","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R51-20261001","first-page":"375","article-title":"Pulmonary arterial hypertension incidence in patients with systemic sclerosis treated with bosentan for digital ulcers: evidence from the SPRING-SIR Registry","volume":"52","author":"Cacciapaglia","year":"2025","journal-title":"J Rheumatol"},{"key":"R52-20261001","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"R53-20261001","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"R54-20261001","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"R55-20261001","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/CIRCULATIONAHA.124.069340","article-title":"Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a randomized controlled phase 3 study","volume":"150","author":"Hoeper","year":"2024","journal-title":"Circulation"},{"key":"R56-20261001","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/hmg\/dds073","article-title":"BMPR-II deficiency elicits pro-proliferative and antiapoptotic responses through the activation of TGFbeta-TAK1-MAPK pathways in PAH","volume":"21","author":"Nasim","year":"2012","journal-title":"Hum Mol Genet"},{"key":"R57-20261001","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCRESAHA.122.321554","article-title":"BMPR2 mutation and metabolic reprogramming in pulmonary arterial hypertension","volume":"132","author":"Cuthbertson","year":"2023","journal-title":"Circ Res"},{"key":"R58-20261001","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1074\/jbc.M114.591057","article-title":"Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension","volume":"290","author":"Prewitt","year":"2015","journal-title":"J Biol Chem"},{"key":"R59-20261001","doi-asserted-by":"crossref","first-page":"L604","DOI":"10.1152\/ajplung.00309.2011","article-title":"BMP type II receptor deficiency confers resistance to growth inhibition by TGF-beta in pulmonary artery smooth muscle cells: role of proinflammatory cytokines","volume":"302","author":"Davies","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R60-20261001","doi-asserted-by":"crossref","first-page":"H677","DOI":"10.1152\/ajpheart.91519.2007","article-title":"Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice","volume":"295","author":"Song","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R61-20261001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"International","year":"2000","journal-title":"Nat Genet"},{"key":"R62-20261001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","article-title":"BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis","volume":"4","author":"Evans","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R63-20261001","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/316947","article-title":"BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension","volume":"68","author":"Machado","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R64-20261001","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/01.CIR.0000012754.72951.3D","article-title":"Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor","volume":"105","author":"Atkinson","year":"2002","journal-title":"Circulation"},{"key":"R65-20261001","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"R66-20261001","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1038\/s41598-022-11435-x","article-title":"Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension","volume":"12","author":"Joshi","year":"2022","journal-title":"Sci Rep"},{"key":"R67-20261001","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.chest.2025.07.4083","article-title":"Sotatercept and the development of pericardial effusions: an emerging safety signal","volume":"169","author":"Larson","year":"2026","journal-title":"Chest"},{"key":"R68-20261001","doi-asserted-by":"crossref","first-page":"2501040","DOI":"10.1183\/13993003.01040-2025","article-title":"Pericardial effusions and sotatercept therapy in pulmonary arterial hypertension: a multicentre, real-world experience","volume":"66","author":"Sahay","year":"2025","journal-title":"Eur Respir J"},{"key":"R69-20261001","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/CIRCULATIONAHA.126.079918","article-title":"Sotatercept for combined post and precapillary pulmonary hypertension associated with heart failure: results from the phase 2, randomized, placebo-controlled CADENCE Study","volume":"153","author":"Gomberg-Maitland","year":"2026","journal-title":"Circulation"},{"issue":"(Suppl 1)","key":"R70-20261001","doi-asserted-by":"crossref","first-page":"A7095","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7095","article-title":"Sotatercept improves hypoxia and clinical status in patients with pulmonary venous occlusive disease","volume":"211","author":"Gomez Rojas","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"R71-20261001","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"key":"R72-20261001","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar2821","article-title":"Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations","volume":"11","author":"Gourh","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R73-20261001","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1183\/09031936.00151313","article-title":"Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension","volume":"43","author":"Cracowski","year":"2014","journal-title":"Eur Respir J"},{"key":"R74-20261001","doi-asserted-by":"crossref","first-page":"139067","DOI":"10.1172\/jci.insight.139067","article-title":"Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension","volume":"6","author":"Ntokou","year":"2021","journal-title":"JCI Insight"},{"key":"R75-20261001","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/ATVBAHA.121.317168","article-title":"Caspase-8 promotes pulmonary hypertension by activating macrophage-associated inflammation and IL-1beta (Interleukin 1beta) production","volume":"42","author":"Rong","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R76-20261001","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1465-9921-12-128","article-title":"Kruppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension","volume":"12","author":"Courboulin","year":"2011","journal-title":"Respir Res"},{"key":"R77-20261001","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/CIRCULATIONAHA.122.059435","article-title":"Regnase-1 prevents pulmonary arterial hypertension through mRNA degradation of interleukin-6 and platelet-derived growth factor in alveolar macrophages","volume":"146","author":"Yaku","year":"2022","journal-title":"Circulation"},{"key":"R78-20261001","doi-asserted-by":"crossref","first-page":"e004936","DOI":"10.1161\/CIRCGEN.124.004936","article-title":"Lung single-cell transcriptomics reveal diverging pathobiology and opportunities for precision targeting in scleroderma-associated versus idiopathic pulmonary arterial hypertension","volume":"18","author":"Tuhy","year":"2025","journal-title":"Circ Genom Precis Med"},{"key":"R79-20261001","doi-asserted-by":"crossref","first-page":"2102356","DOI":"10.1183\/13993003.02356-2021","article-title":"Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension","volume":"60","author":"Galkin","year":"2022","journal-title":"Eur Respir J"},{"key":"R81-20261001","doi-asserted-by":"crossref","first-page":"2002463","DOI":"10.1183\/13993003.02463-2020","article-title":"Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension","volume":"59","author":"Toshner","year":"2022","journal-title":"Eur Respir J"},{"key":"R82-20261001","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2008.102400","article-title":"Antiendothelial cell antibodies in systemic sclerosis","volume":"69","author":"Mihai","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R83-20261001","first-page":"527","article-title":"Antiendothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment","volume":"16","author":"Pignone","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"R84-20261001","first-page":"462","article-title":"Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension","volume":"25","author":"Negi","year":"1998","journal-title":"J Rheumatol"},{"key":"R85-20261001","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R86-20261001","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R87-20261001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R88-20261001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"R89-20261001","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ajpath.2015.03.019","article-title":"Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension","volume":"185","author":"Good","year":"2015","journal-title":"Am J Pathol"},{"key":"R90-20261001","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R91-20261001","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ajpath.2011.06.001","article-title":"Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders","volume":"179","author":"Piera-Velazquez","year":"2011","journal-title":"Am J Pathol"},{"key":"R92-20261001","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R93-20261001","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:02:35Z","timestamp":1790834555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001202","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}